^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CDH17 (Cadherin 17)

    i
    Other names: CDH17, Cadherin 17, HPT-1, Intestinal Peptide-Associated Transporter HPT-1, Cadherin 17, LI Cadherin (Liver-Intestine), Liver-Intestine Cadherin, Cadherin-17, Cadherin, Human Intestinal Peptide-Associated Transporter HPT-1, Human Peptide Transporter 1, HPT-1 Cadherin, LI Cadherin, Cadherin-16, LI-Cadherin, CDH16, HPT1
    Associations

    News

    Trials
    15d
    Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Guangzhou Bio-gene Technology Co., Ltd | N=20 --> 0 | Trial completion date: Dec 2028 --> Mar 2026 | Initiation date: Sep 2025 --> Dec 2024 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2028 --> Mar 2026
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date
    |
    GUCY2C (Guanylate Cyclase 2C) • CDH17 (Cadherin 17)
    17d
    CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=36, Recruiting, Zhejiang University | N=18 --> 36 | Trial completion date: Jan 2027 --> May 2028 | Trial primary completion date: Sep 2026 --> Mar 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CDH17 (Cadherin 17)
    |
    cyclophosphamide • fludarabine IV
    21d
    A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors (clinicaltrials.gov)
    P1/2, N=127, Recruiting, DualityBio Inc. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    CDH17 (Cadherin 17)
    1m
    Pro-tumorigenic role of protocadherin 17 and its prognostic significance in Ewing sarcoma. (PubMed, Discov Oncol)
    Collectively, our data indicate that PCDH17 is upregulated in ES and associated with worse survival, and that PCDH17 depletion suppresses malignant phenotypes in vitro. Together, these results nominate PCDH17 as a candidate prognostic biomarker and potential therapeutic target, which merits further validation.
    Journal
    |
    CDH17 (Cadherin 17) • CDH23 (Cadherin Related 23)
    2ms
    BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings. (PubMed, Cancer Res Commun)
    In heavily pretreated patients with GI tumors, BI 905711 monotherapy or with FOLFIRI plus bevacizumab displayed a manageable safety profile and limited clinical activity.
    P1 data • Journal
    |
    CASP3 (Caspase 3) • CASP7 (Caspase 7) • TNFRSF10B (TNF Receptor Superfamily Member 10b) • CDH17 (Cadherin 17)
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • BI 905711
    2ms
    ChefHat-001: Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=164, Not yet recruiting, BigHat Biosciences, Inc.
    New P1/2 trial
    |
    CDH17 (Cadherin 17)
    3ms
    CDH17 facilitates β-catenin nuclear translocation to reduce drug sensitivity in cisplatin-resistant gastric cancer cells. (PubMed, Neoplasma)
    In conclusion, CDH17 promotes the expression and nuclear translocation of β-catenin in GC cells, leading to activation of the Wnt/β-catenin signaling pathway, which subsequently upregulates ABCB1/P-gp expression and enhances cellular capacity for DDP efflux. These findings imply that targeting CDH17 could be a potential strategy for overcoming chemotherapy resistance in GC.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • ABCC1 (ATP Binding Cassette Subfamily C Member 1) • ABCC2 (ATP Binding Cassette Subfamily C Member 2) • CDH17 (Cadherin 17)
    |
    cisplatin
    3ms
    Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients (clinicaltrials.gov)
    P1, N=33, Completed, Arbele Pty Ltd | Recruiting --> Completed | N=68 --> 33 | Trial completion date: May 2026 --> Jul 2025 | Trial primary completion date: Mar 2026 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CDH17 (Cadherin 17)
    |
    Tecentriq (atezolizumab) • cabotamig (ARB202)
    3ms
    Integrative Transcriptomic Profiling Reveals Molecular Signatures of Disease Progression from Gastroesophageal Reflux Disease to Barrett's Esophagus: A Foundation for Single-Cell Resolution Studies. (PubMed, SLAS Technol)
    This comprehensive transcriptomic study unveils the molecular complexity underlying GERD-to-Barrett's esophagus progression, identifying key genes and pathways that drive pathological transformation.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CDH17 (Cadherin 17) • MMP7 (Matrix metallopeptidase 7)
    3ms
    JianPi QingRe HuoXue Formula targets Cadherin-17 to induce apoptosis in chronic atrophic gastritis with intestinal metaplasia. (PubMed, Phytomedicine)
    JQHF exerts a positive therapeutic effect on CAG with IM without causing significant adverse effects. Its mechanism of action appears to involve targeting CDH17 to modulate the Notch pathway and induce apoptosis.
    Journal
    |
    CDH17 (Cadherin 17)
    4ms
    Integrative transcriptomic and machine learning analysis identifies CDH17 and HOXC13 as robust candidate prognostic biomarkers in uveal melanoma. (PubMed, Comput Biol Med)
    Our integrative approach identifies CDH17 and HOXC13 as biologically relevant, stage-associated prognostic biomarkers in UM. These findings provide a foundation for mechanistic studies and potential translational applications, including therapeutic targeting and risk-stratified patient management.
    Journal
    |
    CDH17 (Cadherin 17) • FABP5 (Fatty Acid Binding Protein 5) • HOXC13 (Homeobox C13)